Key result
Remote monitoring for newly implanted cardiac devices increased to 100% during the COVID-19 pandemic compared to 68% in 2019 (p<0.01), safely reducing the need for in-person visits.
Why the study?
The COVID-19 pandemic necessitated reorganizing elective outpatient device clinics, prompting an evaluation of clinical practice and a potential remote monitoring-only care model for CIED patients.
Does a remote monitoring-only strategy for cardiac implantable electronic devices safely reduce in-person visits during the COVID-19 pandemic?
Observational (n=1,676)
No
Does a remote monitoring-only strategy for cardiac implantable electronic devices safely reduce in-person visits during the COVID-19 pandemic?
Absolute Event Rate: 100% vs 68%
p-value: p=<0.01
A remote monitoring-only strategy for CIEDs during the COVID-19 pandemic successfully reduced in-person visits while safely detecting clinical events.
RM adoption rose sharply during COVID in one center; extends feasibility data but leaves open routine RM-only practice.
Funding Acknowledgements Type of funding sources: None. Introduction COVID-19 pandemic has caused a necessary reorganization of the elective outpatient device clinic. Remote monitoring (RM) of cardiac implantable electronic devices (CIEDs) has already been validated as a safe and effective tool to follow patients, limiting the need for in-person visits. Aim of our study was providing a snapshot of the current clinical practice in a tertiary electrophysiology center in Italy and suggesting a potential model of care for patients with CIEDs. Methods and Results Before the COVID-19 pandemic, patients with implantable cardioverter defibrillators/cardiac resynchronization therapy (ICD/CRTs) were evaluated in the device clinic twice a year and patients with pacemakers (PMs) once a year; loop recorder (ILR) patients were followed remotely only. In the COVID-19 period (March 2020-February 2021) RM was implemented for all compatible CIEDs. Patients with RM were not seen in clinic anymore and were followed with RM. In the COVID-19 period, 100% of newly implanted devices received RM (82 ILR, 194 PMs, 80 ICDs/CRTs), compared to 68% in the same months of 2019 (106/106 ILR, 83/203 PMs, 78/82 ICD/CRTs), p<0.01. In addition, 502 previously implanted patients with RM compatible devices were contacted and received RM in the COVID-19 period. By the end of February 2021, a total of 1676 patients were remotely monitored at our Institution, with a potential saving of outpatient visits of 1683 visits/year, against an average of 8514 RM transmissions/year needing evaluation. During the study period, we observed 213 clinical events that triggered an urgent manual transmission and/or required physician’s intervention (table 1), successfully resolved over the following 24 h. None of the 1676 patients presented to the emergency room with a problem that went unnoticed by the RM system. Conclusion RM of CIEDs is an essential tool to reduce in-person visits during the COVID-19 pandemic and seems to be safe in terms of events detection. The potential for elective outpatient appointments reduction has to be counterbalanced by the sustainability of a large number of transmissions and data to analyze.
No takes yet. Share an insight, caveat, or question.
Ebrille et al. (2023) conducted an observational in Cardiac implantable electronic devices (CIEDs) (n=1,676). Remote monitoring vs. Pre-COVID-19 clinical practice (in-person visits) was evaluated on Proportion of newly implanted devices receiving remote monitoring (p=<0.01). Remote monitoring for newly implanted cardiac devices increased to 100% during the COVID-19 pandemic compared to 68% in 2019 (p<0.01), safely reducing the need for in-person visits.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: